Approved indication: Firdapse is FDA-approved as a potassium channel blocker for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children 6 years of age and older, regardless of whether LEMS is associated with cancer.

Off-label uses: Amifampridine (the active ingredient) is also used off-label, usually by specialists, for certain congenital myasthenic syndromes and other rare neuromuscular transmission disorders, based mainly on small clinical trials and case series rather than large, definitive studies.

Efficacy expectations: Many patients notice improvement in muscle strength, reduced fatigability, and better ability to perform daily activities once an effective dose is reached, often within days to a few weeks as the dose is titrated; symptoms typically worsen again if the drug is stopped. In clinical trials in LEMS, Firdapse produced clinically meaningful improvements in standardized strength scores and patient global impression compared with placebo. Compared with older, nonapproved compounded 3,4-diaminopyridine products, Firdapse offers standardized dosing, safety monitoring, and clear labeling but has similar symptomatic efficacy; other treatments such as pyridostigmine or immunotherapies (steroids, IVIG, or other immunosuppressants) may be added for further benefit or for control of the underlying autoimmune disease.

Typical dosing and how to take it: Firdapse is taken by mouth in 3 to 5 divided doses per day and may be taken with or without food. For adults and children 6 years and older who weigh at least 45 kg (about 99 lb), the usual starting total daily dose is 15–30 mg divided into several doses, increasing by 5 mg per day every 3–4 days as needed and tolerated, up to a maximum single dose of 20 mg and a maximum total of 100 mg per day. For children 6 years and older who weigh less than 45 kg, the starting total daily dose is typically 5–15 mg, with smaller 2.5 mg increases every 3–4 days, up to a maximum single dose of 10 mg and a maximum total of 50 mg per day.

Special dosing situations: In patients with kidney or liver impairment, or in known NAT2 poor metabolizers, treatment should begin at the lowest recommended starting daily dose with slow titration and close monitoring for adverse effects. Tablets are 10 mg and functionally scored so they can be split to obtain 5 mg doses; for patients who cannot swallow tablets or need doses in smaller increments, a pharmacist can prepare an oral suspension (for example, 1 mg/mL) from the tablets according to the instructions in the prescribing information.

Administration tips: Doses should be spaced roughly evenly while awake; do not take more than two tablets (20 mg) at once, and do not exceed the prescribed total daily limit. Try to take doses at the same times each day to keep the drug level steady.

Missed doses and overdose: If a dose is missed, skip it and take the next dose at the regular time—do not double up to make up for a missed dose. In case of suspected overdose (for example, taking more than the prescribed total daily amount or experiencing severe symptoms such as seizures, extreme weakness, or severe nausea), seek emergency medical care or contact a poison control center immediately.

Common side effects: The most frequent side effects include tingling or "pins and needles" sensations in the mouth, face, hands, or feet, upper respiratory infections (cold-like symptoms), stomach pain, nausea, diarrhea, headache, back pain, increased blood pressure, mild muscle spasms, and elevated liver enzymes on blood tests. These effects often appear early in treatment or after dose increases and are usually mild to moderate but can occasionally lead to dose reduction or stopping the drug.

Serious or rare adverse effects: Firdapse can cause seizures, even in people with no prior history, and it must not be used in anyone who has ever had a seizure. Severe allergic reactions, including anaphylaxis (trouble breathing, throat or tongue swelling, hives), can occur and require stopping the drug and urgent medical care. Less commonly, significant increases in liver enzymes, marked blood pressure elevation, or severe weakness, dizziness, or visual changes may occur and should prompt immediate medical attention.

Warnings and precautions: Firdapse is contraindicated in patients with a history of seizures or known hypersensitivity to amifampridine or other aminopyridines. People with kidney or liver impairment and known N-acetyltransferase 2 (NAT2) poor metabolizers should start at the lowest recommended dose and be monitored closely for side effects. Safety and effectiveness are established only for patients 6 years and older. In pregnancy, animal data suggest potential fetal harm and human data are limited, so use is reserved for situations where the expected benefit outweighs potential risk; a pregnancy registry is available in the United States. It is not known if Firdapse passes into human breast milk, so clinicians weigh the benefits of breastfeeding and maternal treatment when making recommendations.

Relative safety compared with other options: Unlike long-term immunosuppressive therapies used in LEMS, Firdapse does not directly suppress the immune system, but it does carry specific neurologic risks (notably seizures) and neurologic sensory symptoms. When dosed carefully and monitored, most patients tolerate it reasonably well, but those with seizure risk factors or significant organ impairment may face higher risk.

Reporting side effects and safety updates: Patients and caregivers can report suspected side effects to the FDA MedWatch program (online or at 1-800-FDA-1088) or to the manufacturer’s safety line listed in the prescribing information. Up-to-date safety communications and labeling changes are posted on the FDA’s drug information pages and in the full prescribing information for Firdapse.

Drug interactions: Firdapse can increase seizure risk when taken with other medicines that lower the seizure threshold, such as certain antidepressants (for example, bupropion or tricyclics), tramadol and some other pain medicines, theophylline, or other stimulatory agents. Drugs with cholinergic effects, including cholinesterase inhibitors like pyridostigmine or neostigmine, may intensify cholinergic side effects (such as cramping, diarrhea, or sweating) when combined. Use with other aminopyridines or compounded 3,4-diaminopyridine products, including dalfampridine, should generally be avoided to prevent overdose and overlapping toxicity.

Food, alcohol, and supplements: No specific food interactions are known, and Firdapse can be taken with or without meals. The effect of alcohol on Firdapse has not been well studied, but because alcohol can lower the seizure threshold in some people, many clinicians advise limiting or avoiding alcohol, especially during dose titration. Patients should tell their prescriber about all prescription and over-the-counter medicines, vitamins, and herbal supplements they use, since many products can influence seizure risk or blood pressure.

Conditions requiring extra caution: Firdapse must not be used in anyone with a history of seizures or in patients with known hypersensitivity to amifampridine or other aminopyridines. People with kidney or liver disease require lower starting doses and careful titration, and those with uncontrolled hypertension or significant cardiovascular disease should be monitored because Firdapse can raise blood pressure. Coexisting neurologic conditions that predispose to seizures, or concurrent use of multiple pro-convulsant drugs, further increase risk.

Monitoring needs: Clinicians typically monitor for neurologic symptoms (new tingling, confusion, or seizure activity), blood pressure changes, and, in some patients, liver enzyme levels, especially during dose adjustments or in those with pre-existing liver disease. Patients and caregivers should promptly report new or worsening neurologic symptoms, significant blood-pressure elevations, or any signs of allergic reactions.

Q: What does Firdapse treat?
A: Firdapse is used to improve muscle strength and reduce fatigue in people 6 years and older who have Lambert-Eaton myasthenic syndrome, a rare autoimmune disease that affects the communication between nerves and muscles.

Q: How long does it take for Firdapse to start working?
A: Many people notice some improvement in strength or stamina within days to a few weeks, but the dose is usually increased gradually over several weeks to find the best balance of benefit and side effects.

Q: How often do I have to take Firdapse each day?
A: Firdapse is taken several times a day—typically 3 to 5 doses spread out while you are awake—because its effects wear off within a few hours.

Q: Can I take Firdapse with food or other daily medicines?
A: You can take Firdapse with or without food, but you should review all your other prescription and nonprescription medicines with your doctor or pharmacist because some drugs can interact with Firdapse or raise the risk of seizures.

Q: What should I do if I miss a dose of Firdapse?
A: If you miss a dose, simply skip it and take your next scheduled dose at the usual time; do not double the next dose to make up for the one you missed.

Q: Is Firdapse a cure for LEMS?
A: Firdapse is not a cure and does not stop the immune system from attacking nerve endings, but it can significantly improve day-to-day symptoms by helping nerves release more of the chemical signal needed for muscles to work.

Storage: Store Firdapse tablets at room temperature, about 68°F to 77°F (20°C to 25°C), in the original container, tightly closed and protected from excess moisture, and keep all medication out of the reach of children.

Liquid suspension (if prepared by a pharmacy or caregiver): Store the prepared oral suspension in a refrigerator (about 36°F to 46°F or 2°C to 8°C) and use it within 24 hours; discard any remaining liquid after 24 hours.

Disposal: Safely throw away tablets or suspension that are expired, damaged, or no longer needed, preferably through a medicine take-back program or according to pharmacist or local waste-disposal instructions, and never share Firdapse with others.